Quest Diagnostics Expands Services and Advances in Cancer Research
Quest Diagnostics Inc, a leading healthcare provider, has made significant strides in recent times, solidifying its position as a trusted partner in the medical community. The company’s latest move involves the completion of its acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories. This strategic acquisition has expanded Quest Diagnostics’ services in renal-specific laboratory testing, positioning the company to provide dialysis-related clinical testing to independent dialysis clinics.
This expansion is a significant development for Quest Diagnostics, as it enables the company to cater to the growing needs of the dialysis community. By providing specialized testing services, Quest Diagnostics is helping to improve patient outcomes and enhance the quality of care for individuals undergoing dialysis treatment.
In addition to its acquisition, Quest Diagnostics’ subsidiary, Haystack Oncology, has collaborated with Mass General Brigham to conduct clinical trials studying a ctDNA minimal residual disease test. This innovative test aims to guide post-surgical treatment decisions for certain cancer types, offering patients and healthcare providers a valuable tool in the fight against cancer.
The company’s stock price has shown a moderate increase over the past year, with a recent close price above its 52-week high. This upward trend is a testament to Quest Diagnostics’ commitment to innovation and its ability to stay ahead of the curve in the rapidly evolving healthcare landscape.
Key Highlights:
- Quest Diagnostics has completed its acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories
- The company has expanded its services in renal-specific laboratory testing
- Haystack Oncology has collaborated with Mass General Brigham to conduct clinical trials studying a ctDNA minimal residual disease test
- Quest Diagnostics’ stock price has shown a moderate increase over the past year, with a recent close price above its 52-week high